Extended Data Fig. 4: Impact of induction of Interferon-γ signalling in a fraction of anti-PD-1/PD-L1 relapsed/refractory last-line cancer on CXCL10 levels.
From: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
(a) Significant induction and maintenance of chemokine CXCL-10 following treatment for six weeks in the blood of phase 2a NSCLC, HCC and UC study participants. P values are reported from repeated measures ANOVA with Geisser-Greenhouse correction followed by Dunnett’s test corrected for multiple comparisons. (b) Baseline CXCL-10 levels between participant with best overall response (BOR) according to RECIST 1.1 of PD/SD (grey) and PR/CR (green). P values are reported from two-tailed Mann-Whitney test. (c) Heatmap representing higher mean values [pg/ml] of CXCL-10 following treatment in participants with BOR of PR or CR (lower row) compared to participants with BOR of PD or SD (upper row). (a-c) Boxplots centre line, median; box, IQR; whiskers, 1.5 x IQR; outliers are depicted individually.
